Impact of Big Pharma Organizational Structure on R&D ProductivityBoD – Books on Demand, 2009 - 143 pages |
Contents
Definition and explanation of key terms | 9 |
Common organizational settings for companies | 47 |
1 | 51 |
Presentation and evaluation of the Big Pharma companies 4 1 Introduction | 73 |
Average RD sales ratio and innovation in Big Pharma | 101 |
Average RD input and innovation in Big Pharma | 107 |
Common terms and phrases
Annual Report approved drug approved NMEs AstraZeneca Aventis balanced scorecard based on annex Big Pharma Big Pharma companies blockbuster drugs centre chapter clinical Company profile company ROI Datamonitor decentralized discovery Drug Authority EMEA European Medicine Evaluation example figure based Five-year Food and Drug Gassmann Genentech geographic GlaxoSmithKline global health authorities Holtbrügge hub model Hungenberg Johnson & Johnson matrix structure Medicine Evaluation Agency Merck Microsoft multinational NME approvals NMEs in phase Novartis organizational structure output patents Pfizer Pharma R&D pharmaceutical companies pharmaceutical firms pharmaceutical industry Pharmaceutical Research pipeline polycentric pre-clinical development process innovation product innovation R&D expenditure R&D organization R&D process R&D productivity R&D sales ratio R&D spent R&D structure R&D units Reepmeyer Reger research and development Roche Sanofi-Aventis Schöffski Source strategy table based therapeutic areas tion Total NME projects total sales Toyota Tushman Vioxx Welge Wulf Zedtwitz